Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-01

FDA Approved: FABRAZYME — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Fabrazyme (agalsidase beta) from Genzyme Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FABRAZYME (Agalsidase beta)

Snippet

SUPPL AP for FABRAZYME (AGALSIDASE BETA)